Central nervous system cancers.
Primary and metastatic tumors of the central nervous system are a heterogeneous group of neoplasms with varied outcomes and management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemotherapy and radiation as the new standard for treating patients with pure or mixed anaplastic oligodendroglioma harboring the 1p/19q codeletion. For metastatic disease, increasing evidence supports the efficacy of stereotactic radiosurgery in treating patients with multiple metastatic lesions but low overall tumor volume. These guidelines provide recommendations on the diagnosis and management of this group of diseases based on clinical evidence and panel consensus. This version includes expert advice on the management of low-grade infiltrative astrocytomas, oligodendrogliomas, anaplastic gliomas, glioblastomas, medulloblastomas, supratentorial primitive neuroectodermal tumors, and brain metastases. The full online version, available at NCCN. org, contains recommendations on additional subtypes.
Published In/Presented At
Nabors, L. B., Ammirati, M., Bierman, P. J., Brem, H., Butowski, N., Chamberlain, M. C., DeAngelis, L. M., Fenstermaker, R. A., Friedman, A., Gilbert, M. R., Hesser, D., Holdhoff, M., Junck, L., Lawson, R., Loeffler, J. S., Maor, M. H., Moots, P. L., Morrison, T., Mrugala, M. M., Newton, H. B., … National Comprehensive Cancer Network (2013). Central nervous system cancers. Journal of the National Comprehensive Cancer Network : JNCCN, 11(9), 1114–1151. https://doi.org/10.6004/jnccn.2013.0132
Medicine and Health Sciences
Department of Medicine